| Diabetes Mellitus, Non-Insulin-Dependent
Segluromet vs Steglatro
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Segluromet vs Steglatro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSteglatro has a higher rate of injection site reactions vs Segluromet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Steglatro but not Segluromet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Segluromet
Steglatro
At A Glance
Oral
Twice daily
SGLT2 inhibitor/biguanide
Oral
Daily
SGLT2 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Individualize starting dosage; take orally twice daily with meals; maximum recommended dosage is 7.5 mg ertugliflozin/1,000 mg metformin HCl per dose (15 mg/2,000 mg daily); not recommended if eGFR <45 mL/min/1.73 m2; contraindicated if eGFR <30 mL/min/1.73 m2, ESRD, or dialysis.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily in the morning, with or without food; may increase to 15 mg once daily for additional glycemic control; not recommended when eGFR < 45 mL/min/1.73 m2; withhold at least 4 days prior to surgery or procedures associated with prolonged fasting.
Contraindications
- Hypersensitivity to ertugliflozin, metformin, or any excipient in SEGLUROMET
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end stage-renal disease (ESRD), or dialysis
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
- Hypersensitivity to ertugliflozin or any excipient in STEGLATRO (reactions including angioedema have occurred)
Adverse Reactions
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Most common (>=5%, metformin) Diarrhea, nausea, vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia, Fournier's Gangrene, vitamin B12 deficiency
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), angioedema, rash (ertugliflozin); cholestatic, hepatocellular, and mixed hepatocellular liver injury (metformin)
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis in type 1 diabetes, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia with insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), genital mycotic infections
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), angioedema, rash
Pharmacology
Ertugliflozin is an SGLT2 inhibitor that reduces renal glucose reabsorption and lowers the renal threshold for glucose, increasing urinary glucose excretion; metformin HCl is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity.
SGLT2 inhibitor; ertugliflozin inhibits SGLT2, the predominant transporter responsible for renal reabsorption of filtered glucose, thereby lowering the renal threshold for glucose and increasing urinary glucose excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Segluromet
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (10/12) · Qty limit (9/12)
Steglatro
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Segluromet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (2/8) · Qty limit (1/8)
Steglatro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Segluromet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Steglatro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Segluromet.
No savings programs available for Steglatro.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SeglurometView full Segluromet profile
SteglatroView full Steglatro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.